What Is Allarity Therapeutics, Inc. (ALLR) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, the balance of valuation evidence tilts cautious on Allarity Therapeutics, Inc. at its current price of $1.18. The composite intrinsic value is estimated at $0.92 (-21.9% average return), with 7 models flagging overvaluation risk. Model dispersion is worth noting: ML-RIV targets $2.37 (+100.7%), versus Sentiment SOTP at $0.06 (-94.7%). This +195.4% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About ALLR?
10 of 13 models are currently active for ALLR. Of these, 3 models suggest upside while 7 models suggest overvaluation. The Bayesian DCF estimates ALLR's intrinsic value at $0.58, implying -50.5% downside from the current price. See which stocks rank higher →
How Does ALLR Rank in Biotechnology?
Among 76 Biotechnology stocks, ALLR ranks #68 by Quality of Company score. CirclFi's QOC score of 3.7/10 evaluates 32 fundamental signals. A score of 3.7 signals below-average fundamentals.
See all Most Undervalued Biotechnology Stocks →
Within the Biotechnology space, Allarity Therapeutics, Inc. competes in an environment where pipeline depth and stage distribution often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.
Is ALLR a Value Trap?
CirclFi's Value Trap algorithm assigns ALLR a score of 36/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
10 of 13 models are active for Allarity Therapeutics, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Allarity Therapeutics, Inc. is rated at 3.7/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.
The gap between the most bullish and bearish model spans +195.4% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every ALLR valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across ALLR's 10 active models, average confidence is 27%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad